Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 2/3 1

Status

Completed 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Endocrine 1

Conditions

Testicular Neoplasms 1Prostatic Neoplasms 1Prostate Cancer Recurrent 1Klinefelter Syndrome 1Infertility 1Hypogonadism 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × testosterone undecanoate × Genitourinary × Clear all
NCT05081193 2025-09-22

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
15 enrolled
Genitourinary

Prostatic Neoplasms

NCT04134130 2020-01-22

The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer

Lund University

Phase NA Completed
33 enrolled
Genitourinary

Prostate Cancer Recurrent

NCT03379012 2019-10-22

FARETES

Kidney Cancer Research Bureau

Phase 2 Completed
60 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT01206270 2018-09-25

ALCeP

University of Roma La Sapienza

Phase 2/3 Completed
56 enrolled
Genitourinary

Hypogonadism, Infertility, Klinefelter Syndrome, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡